Reflecting on DeepMind’s AlphaFold artificial intelligence success – what’s the real significance for protein folding research and drug discovery? 13 Aug 2021 In a long read, Professor Paul Workman, Chief Executive and President of the ICR, and also a drug discovery scientist, reflects on the significance of the latest version of AlphaFold – a powerful AI system that has been applied to predict structures for almost 99% of human proteins – for fundamental research and drug discovery. Find out more Show/Hide
Funding cuts create perfect storm that could capsize cancer research in the UK 29 Mar 2021 The UK’s science budget faces catastrophic cuts – on top of the alarming impact of Covid-19 on medical research organisations. Professor Paul Workman, Chief Executive of the ICR, warns that without a change in course from the Government, cancer research in the UK is heading for a perfect storm with an impact that could last decades. Find out more Show/Hide
Trying to drug the apparently undruggable, and what it can teach us 04 Nov 2020 Professor Paul Workman reflects in depth on his experience in trying to drug a particularly challenging cancer target, and why it is always important to be clear about the risks and benefits of a drug discovery project – and to share the results with the research community. Find out more Show/Hide
Climbing the peaks of drug discovery – tackling the most challenging targets with ingenuity and realism 21 Oct 2020
Our manifesto for cancer drug discovery and development – focusing on innovation to tackle treatment resistance and meeting patients’ needs 30 Apr 2019
Why regulators must move with the science if we’re to get innovative new treatments to patients more quickly 05 Dec 2018